NFX Nuformix Plc

TIDMNFX

RNS Number : 5717A

Nuformix PLC

25 May 2023

25 May 2023

Nuformix plc

("Nuformix" or the "Company")

Change of Auditor

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the appointment of Kreston Reeves LLP ("Kreston Reeves") as auditor to the Company. The appointment of Kreston Reeves will be subject to approval by shareholders at the next Annual General Meeting of the Company.

Enquiries:

 
 Nuformix plc 
 Dr Dan Gooding, Executive Director         Via IFC Advisory 
 Stanford Capital Partners Limited 
 Tom Price / Patrick Claridge (Corporate 
  Finance)                                  +44 (0) 20 3650 3650 
 John Howes (Corporate Broking)             +44 (0) 20 3650 3652 
 IFC Advisory Limited 
 Tim Metcalfe                               +44 (0) 20 3934 6630 
  Zach Cohen                                 nuformix@investor-focus.co.uk 
 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPEAXSLASSDEFA

(END) Dow Jones Newswires

May 25, 2023 02:00 ET (06:00 GMT)

Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024